While Biogen’s tau-targeting therapy didn’t demonstrate improvement on a dementia severity scale, the company touted ...
Shares of REGENXBIO declined 37% on a mixed data readout and other updates from the company's first quarter earnings call Thursday.
In a letter to President Donald Trump, a group of biotech executives recommended former cancer regulator Richard Pazdur to ...
Isomorphic Labs, which hasn’t yet disclosed a molecule or reached the clinic, breaks the recent trend of investors putting ...
After a 12-month period that saw the Belgian biotech consider a spinout, swap out CEOs, and enter a three-way acquisition ...
Three pharma CEOs joined the $30 million compensation club in 2025 but Eli Lilly’s David Ricks exceeded his nearest peer by ...
Scientists who focus only on generating data risk missing their role in shaping strategy and driving innovation.
The FDA's decision last year to make complete response letters public provides new insight into why therapies sometimes fail ...
New guidelines from two leading medical associations suggest that efforts to reduce bad cholesterol should focus on ...
The widely covered impending ouster of FDA Commissioner Marty Makary not long after the exit of controversial biologics head ...
The FDA turned away Ebvallo in January, taking issue with the design of the registrational trial. In a recent meeting, however, the agency agreed that the study could in fact support the cell ...
Partner Therapeutics announced last week that the FDA had granted Bizengri a Commissioner’s National Priority Voucher to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results